Categories: All postsCannabis

Acreage Holdings could be the Proctor and Gamble of pot, Beacon Securities says

Beacon Securities analyst Russell Stanley is bullish about US cannabis company Acreage Holdings (Acreage Holdings Stock Quote, Chart CSE:ACRG.U), which he thinks could become the Proctor & Gamble of the cannabis space.

Makers and distributors of cannabis-based edibles and beverages, Acreage announced on Thursday an agreement to acquire Form Factory, a multi-state manufacturer and distributor of cannabis products formed from co-packer Gesundheit Foods and IP portfolio, Made by Science, in an all-stock transaction worth $160 million. (All figures in US dollars.) Form Factory currently employs 51 people across three states, with Acreage saying that the entity should start contributing to revenue in 2019 and become EBITDA accretive in 2020.

Stanley says that while the purchase doesn’t move his estimates or target price, he views it positively from a strategic perspective.

“Acreage expects this transaction to make it the first national consumer packaged goods (CPG) company in the United States, positioning it well to partner with traditional CPG heavyweights such as Nestle, Mars or Procter & Gamble,” says Stanley in an update to clients on Thursday. “During this morning’s call, management stressed that the company still intends to develop its own brand portfolio, and this transaction is designed to accelerate Acreage’s own product development, while adding a new line of business that leverages the company’s extensive footprint.”

The analyst sees Acreage generating revenue in 2018, 2019 and 2020 of $69 million, $272 million and $533 million, respectively, and Adj. EBITDA in 2018, 2019 and 2020 of negative $13 million, $60 million and $158 million, respectively.

Stanley maintains his “Buy” rating and $40.00 target price, which represents a potential return of 150 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: acrg.u
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

4 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

11 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

11 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

12 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

1 day ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

1 day ago